FY2016
生效日期
- 首次收录
Other endocrine disorders
类别 — 请选择更具体的编码
CDC/NCHS · FY2016pseudohypoparathyroidism (E20.1)
首次收录 · 2015-10-01
自首次收录以来无变更记录
生效日期
Other endocrine disorders
类别 — 请选择更具体的编码
CDC/NCHS · FY2016| 所有版本 | 生效日期 | 编码历史 |
|---|---|---|
| FY2016 | 2015-10-01 | 首次收录 |
| FY2017 | 2016-10-01 | 分类表无变更 |
| FY2018 | 2017-10-01 | 分类表无变更 |
| FY2019 | 2018-10-01 | 分类表无变更 |
| FY2020 | 2019-10-01 | 分类表无变更 |
| FY2020 · April | 2020-04-01 | 分类表无变更 |
| FY2021 | 2020-10-01 | 分类表无变更 |
| FY2021 · 01-01 | 2021-01-01 | 分类表无变更 |
| FY2022 | 2021-10-01 | 分类表无变更 |
| FY2022 · 04-01 | 2022-04-01 | 分类表无变更 |
| FY2023 | 2022-10-01 | 分类表无变更 |
| FY2023 · 04-01 | 2023-04-01 | 分类表无变更 |
| FY2024 | 2023-10-01 | 分类表无变更 |
| FY2024 · 04-01 | 2024-04-01 | 分类表无变更 |
| FY2025 | 2024-10-01 | 分类表无变更 |
| FY2025 · 04-01 | 2025-04-01 | 分类表无变更 |
| FY2026 | 2025-10-01 | 分类表无变更 |
| FY2026 · April | 2026-04-01 | 分类表无变更 |
| FY2027 | 2026-10-01 | 分类表无变更 |
pseudohypoparathyroidism (E20.1)
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
E34.0Carcinoid syndrome类别：需要更具体的编码E34.1Other hypersecretion of intestinal hormones可计费的具体编码E34.2Ectopic hormone secretion, not elsewhere classified可计费的具体编码E34.3Short stature due to endocrine disorder类别：需要更具体的编码E34.4Constitutional tall stature可计费的具体编码E34.5Androgen insensitivity syndrome类别：需要更具体的编码E34.8Other specified endocrine disorders可计费的具体编码E34.9Endocrine disorder, unspecified可计费的具体编码官方名称和说明保留来源语言。 官方来源 ↗
Code first · endocrine disease, except diabetes (E00-E07, E15-E16, E20-E34)
Note · All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.